Peter Palese | Academic Influence

Peter Palese's AcademicInfluence.com Rankings

Peter Palese

Biology

#720

World Rank

#1257

Historical Rank

Virology

#23

World Rank

#25

Historical Rank

biology Degrees

Download Badge

Biology

Peter Palese's Degrees

PhD Microbiology University of Chicago
Doctorate Medicine University of Chicago

Why Is Peter Palese Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter Palese is a United States microbiologist, researcher, inventor and the Horace W. Goldsmith Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai in New York City, and an expert in the field of RNA viruses.

(See a Problem?)

Peter Palese's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Influenza Virus Transmission Is Dependent on Relative Humidity and Temperature (2007) (1405)
Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus (2005) (1203)
A novel influenza A virus mitochondrial protein that induces cell death (2001) (1040)
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. (1998) (1031)
Human Host Factors Required for Influenza Virus Replication (2010) (825)
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. (1974) (808)
Rescue of influenza A virus from recombinant DNA. (2007) (762)
Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo (2014) (648)
Activation of Interferon Regulatory Factor 3 Is Inhibited by the Influenza A Virus NS1 Protein (2000) (639)
Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists (2006) (620)
The biology of influenza viruses. (2008) (617)
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. (2006) (606)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy (2014) (598)
Influenza A Virus NS1 Protein Prevents Activation of NF-κB and Induction of Alpha/Beta Interferon (2000) (592)
Influenza: old and new threats (2004) (591)
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus (2006) (577)
A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission (2007) (552)
Transmission of Influenza Virus in a Mammalian Host Is Increased by PB2 Amino Acids 627K or 627E/701N (2009) (546)
Pathogenicity of Influenza Viruses with Genes from the 1918 Pandemic Virus: Functional Roles of Alveolar Macrophages and Neutrophils in Limiting Virus Replication and Mortality in Mice (2005) (532)
Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain (2010) (514)
The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins (1998) (504)
Structure of the Uncleaved Human H1 Hemagglutinin from the Extinct 1918 Influenza Virus (2004) (502)
Influenza (2018) (502)
A Single Mutation in the PB1-F2 of H5N1 (HK/97) and 1918 Influenza A Viruses Contributes to Increased Virulence (2007) (487)
Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane (2007) (479)
The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 (2003) (478)
The Ebola virus VP35 protein functions as a type I IFN antagonist. (2000) (466)
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. (2004) (441)
Amplification, expression, and packaging of a foreign gene by influenza virus (1989) (434)
Cross-neutralization of influenza A viruses mediated by a single antibody loop (2012) (401)
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza (2002) (399)
A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor Binding Specificity (2005) (384)
Influenza Virus NS1 Protein Counteracts PKR-Mediated Inhibition of Replication (2000) (378)
Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins (2003) (374)
Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1 (2005) (369)
Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. (1976) (355)
Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950 (1978) (353)
Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies (2013) (348)
Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. (1988) (334)
The guinea pig as a transmission model for human influenza viruses. (2006) (332)
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. (2000) (332)
Positive Darwinian evolution in human influenza A viruses. (1991) (325)
Cellular Proteins in Influenza Virus Particles (2008) (324)
Influenza A Virus PB1-F2 Protein Contributes to Viral Pathogenesis in Mice (2006) (321)
Immune history profoundly affects broadly protective B cell responses to influenza (2015) (317)
The Role of Interferon in Influenza Virus Tissue Tropism (1998) (314)
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS (1994) (312)
Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. (1987) (312)
The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity. (1980) (309)
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. (2016) (306)
Influenza virus hemagglutinin stalk-based antibodies and vaccines. (2013) (301)
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes (2010) (301)
A Proline-Rich Motif within the Matrix Protein of Vesicular Stomatitis Virus and Rabies Virus Interacts with WW Domains of Cellular Proteins: Implications for Viral Budding (1999) (295)
High Temperature (30°C) Blocks Aerosol but Not Contact Transmission of Influenza Virus (2008) (293)
Advances in the development of influenza virus vaccines (2015) (289)
Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes (2001) (282)
The NPI-1/NPI-3 (karyopherin alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal (1997) (277)
Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1 (1986) (277)
Toward a universal influenza virus vaccine: prospects and challenges. (2013) (277)
Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. (1974) (272)
The genes of influenza virus (1977) (271)
Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins (2010) (270)
Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. (1993) (269)
Nuclear Import of Influenza Virus RNA Can Be Mediated by Viral Nucleoprotein and Transport Factors Required for Protein Import (*) (1995) (266)
Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. (1986) (259)
Determination of influenza virus proteins required for genome replication (1990) (256)
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies (2008) (253)
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses (2012) (252)
A plasmid-based reverse genetics system for influenza A virus (1996) (250)
Introduction of site-specific mutations into the genome of influenza virus. (1990) (241)
Attenuation of Equine Influenza Viruses through Truncations of the NS1 Protein (2005) (241)
Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza (2008) (240)
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. (2006) (232)
Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes (2012) (232)
Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. (1988) (229)
Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction (2003) (226)
The Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon at the Level of the MAVS Adaptor Protein (2011) (223)
Advances in the development of influenza virus vaccines (2015) (222)
Differences in RNA patterns of influenza A viruses (1976) (219)
Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic (2007) (215)
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. (2016) (214)
Transmission of Influenza Virus via Aerosols and Fomites in the Guinea Pig Model (2009) (207)
Nipah Virus V and W Proteins Have a Common STAT1-Binding Domain yet Inhibit STAT1 Activation from the Cytoplasmic and Nuclear Compartments, Respectively (2004) (206)
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis (2011) (203)
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans (2014) (203)
Two nuclear location signals in the influenza virus NS1 nonstructural protein (1988) (202)
Variation of influenza A, B, and C viruses. (1982) (200)
Specific Residues of the Influenza A Virus Hemagglutinin Viral RNA Are Important for Efficient Packaging into Budding Virions (2007) (196)
The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structure (1991) (190)
Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 (2020) (190)
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. (2004) (189)
Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines (2010) (189)
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. (2012) (186)
Cellular Splicing Factor RAF-2p48/NPI-5/BAT1/UAP56 Interacts with the Influenza Virus Nucleoprotein and Enhances Viral RNA Synthesis (2001) (183)
Promoter analysis of influenza virus RNA polymerase (1989) (182)
Nuclear Localization of the Nipah Virus W Protein Allows for Inhibition of both Virus- and Toll-Like Receptor 3-Triggered Signaling Pathways (2005) (182)
Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses (2013) (181)
Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. (1987) (180)
Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. (1982) (170)
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus (2008) (166)
Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus (1993) (166)
Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. (2003) (166)
Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon by Binding to MAVS and Decreasing Mitochondrial Membrane Potential (2012) (165)
An Unconventional NLS is Critical for the Nuclear Import of the Influenza A Virus Nucleoprotein and Ribonucleoprotein (2005) (165)
Highly Conserved Regions of Influenza A Virus Polymerase Gene Segments Are Critical for Efficient Viral RNA Packaging (2007) (164)
The E3 protein of bovine coronavirus is a receptor-destroying enzyme with acetylesterase activity (1988) (163)
Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis (2013) (162)
NPI-1, the human homolog of SRP-1, interacts with influenza virus nucleoprotein. (1995) (161)
Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins (2013) (159)
One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis (2012) (157)
A Single N66S Mutation in the PB1-F2 Protein of Influenza A Virus Increases Virulence by Inhibiting the Early Interferon Response In Vivo (2010) (157)
An influenza virus containing nine different RNA segments. (1991) (156)
Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells (1977) (155)
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility (2013) (155)
Making Better Influenza Virus Vaccines? (2006) (154)
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice (2015) (153)
Colocalization of Different Influenza Viral RNA Segments in the Cytoplasm before Viral Budding as Shown by Single-molecule Sensitivity FISH Analysis (2013) (153)
Evolution of human influenza A viruses in nature: recombination contributes to genetic variation of H1N1 strains. (1979) (151)
A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates (2012) (150)
Late Domain Function Identified in the Vesicular Stomatitis Virus M Protein by Use of Rhabdovirus-Retrovirus Chimeras (1999) (149)
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy (2015) (148)
PB1-F2 Expression by the 2009 Pandemic H1N1 Influenza Virus Has Minimal Impact on Virulence in Animal Models (2010) (147)
Mapping of the influenza virus genome: identification of the hemagglutinin and the neuraminidase genes. (1976) (145)
H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice (2013) (145)
Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis (2012) (143)
A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo (2012) (143)
Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. (2013) (141)
Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans (2014) (140)
Recombinant Newcastle Disease Virus as a Vaccine Vector (2001) (140)
Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells (2011) (139)
Negative-strand RNA viruses: genetic engineering and applications. (1996) (138)
7a Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates p38 Mitogen-Activated Protein Kinase (2006) (138)
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial (2020) (138)
Effects of Influenza A Virus NS1 Protein on Protein Expression: the NS1 Protein Enhances Translation and Is Not Required for Shutoff of Host Protein Synthesis (2002) (137)
The influenza C virus glycoprotein (HE) exhibits receptor-binding (hemagglutinin) and receptor-destroying (esterase) activities. (1987) (136)
Guiding the Immune Response against Influenza Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the Globular Head Domain (2013) (135)
Transmission of Pandemic H1N1 Influenza Virus and Impact of Prior Exposure to Seasonal Strains or Interferon Treatment (2009) (135)
Gene composition of high-yielding influenza vaccine strains obtained by recombination. (1980) (133)
Transmission of a 2009 Pandemic Influenza Virus Shows a Sensitivity to Temperature and Humidity Similar to That of an H3N2 Seasonal Strain (2010) (133)
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus (2016) (133)
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus (2002) (132)
NS1-Binding Protein (NS1-BP): a Novel Human Protein That Interacts with the Influenza A Virus Nonstructural NS1 Protein Is Relocalized in the Nuclei of Infected Cells (1998) (131)
Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. (1983) (130)
High-efficiency formation of influenza virus transfectants (1991) (129)
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. (2020) (126)
Temperature-sensitive mutants of influenza WSN virus defective in virus-specific RNA synthesis (1975) (126)
Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets (2014) (126)
The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model (2011) (125)
In Vivo Bioluminescent Imaging of Influenza A Virus Infection and Characterization of Novel Cross-Protective Monoclonal Antibodies (2013) (123)
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus (1995) (122)
Functional Replacement of the Carboxy-Terminal Two-Thirds of the Influenza A Virus NS1 Protein with Short Heterologous Dimerization Domains (2002) (121)
Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). (1974) (118)
Why Do Influenza Virus Subtypes Die Out? A Hypothesis (2011) (118)
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice (2017) (115)
Mapping of the influenza virus genome. III. Identification of genes coding for nucleoprotein, membrane protein, and nonstructural protein (1976) (114)
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. (2015) (113)
Noncumulative sequence changes in the hemagglutinin genes of influenza C virus isolates. (1985) (112)
Unraveling the Mystery of Swine Influenza Virus (2009) (111)
Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans (2016) (109)
Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models (2010) (108)
A genetically engineered influenza A virus with ras-dependent oncolytic properties. (2001) (107)
Oseltamivir-Resistant Influenza A Viruses Are Transmitted Efficiently among Guinea Pigs by Direct Contact but Not by Aerosol (2008) (107)
Sequential mutations in hemagglutinins of influenza B virus isolates: definition of antigenic domains. (1983) (107)
Influenza B Virus NS1-Truncated Mutants: Live-Attenuated Vaccine Approach (2008) (106)
A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies (2017) (105)
Nonconserved nucleotides at the 3' and 5' ends of an influenza A virus RNA play an important role in viral RNA replication. (1996) (104)
RNAs of influenza A, B, and C viruses (1976) (104)
Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein (1978) (104)
Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. (2015) (104)
Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. (1996) (103)
Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. (2016) (103)
Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin (2017) (103)
Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin (2014) (102)
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity (2017) (102)
Hemagglutinin-Pseudotyped Green Fluorescent Protein-Expressing Influenza Viruses for the Detection of Influenza Virus Neutralizing Antibodies (2009) (102)
Defining the antibody cross-reactome against the influenza virus surface glycoproteins (2017) (101)
Plasmid-only rescue of influenza A virus vaccine candidates. (2001) (101)
A Sendai Virus-Derived RNA Agonist of RIG-I as a Virus Vaccine Adjuvant (2012) (101)
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact (2016) (100)
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. (2009) (100)
H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge (2013) (100)
Nonrandom association of parental genes in influenza A virus recombinants. (1979) (99)
Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice (2012) (98)
Influenza C virus hemagglutinin: comparison with influenza A and B virus hemagglutinins (1984) (97)
An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. (1991) (97)
Measles virus phosphoprotein (P) requires the NH2- and COOH-terminal domains for interactions with the nucleoprotein (N) but only the COOH terminus for interactions with itself. (1995) (95)
Expression of a foreign protein by influenza A virus (1994) (95)
Epidemiology of influenza C virus in man: multiple evolutionary lineages and low rate of change. (1986) (94)
Characterization of the polyadenylation signal of influenza virus RNA (1994) (94)
Budding Capability of the Influenza Virus Neuraminidase Can Be Modulated by Tetherin (2011) (94)
Recombinant Paramyxovirus Type 1-Avian Influenza-H7 Virus as a Vaccine for Protection of Chickens Against Influenza and Newcastle Disease (2003) (93)
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes (2017) (92)
Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. (1998) (92)
Mutations at palmitylation sites of the influenza virus hemagglutinin affect virus formation (1994) (90)
Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner (2016) (89)
Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model (2009) (89)
Evolution of human influenza a viruses in nature: Sequential mutations in the genomes of new H1N1 isolates (1979) (89)
Biochemical evidence that "new" influenza virus strains in nature may arise by recombination (reassortment). (1978) (87)
Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity (2008) (86)
Transmission of influenza virus in temperate zones is predominantly by aerosol, in the tropics by contact (2009) (85)
Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. (1993) (84)
Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains. (1980) (84)
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial (2019) (83)
The Influenza A Virus PB2, PA, NP, and M Segments Play a Pivotal Role during Genome Packaging (2012) (82)
The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses (2011) (82)
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form (1992) (82)
Genetic manipulation of negative-strand RNA virus genomes. (1993) (81)
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. (2009) (81)
Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses (2015) (81)
Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries (2010) (80)
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. (2013) (80)
Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1 (1993) (80)
Oligonucleotide mapping: evaluation of its sensitivity by computer- simulation (1982) (79)
H5N1 influenza viruses: Facts, not fear (2012) (77)
Long-term survival of influenza virus infected club cells drives immunopathology (2014) (76)
Determination of the mutation rate of a retrovirus (1988) (76)
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus (2010) (75)
Transmission of Influenza B Viruses in the Guinea Pig (2012) (75)
Influenza A virus PB1-F2: a small protein with a big punch. (2007) (74)
Effective replication of human influenza viruses in mice lacking a major alpha2,6 sialyltransferase. (2007) (74)
Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones (2015) (72)
Efficient expression of influenza virus NS1 nonstructural proteins in Escherichia coli. (1983) (71)
Mutational analysis of the promoter required for influenza virus virion RNA synthesis (1992) (71)
Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus (1994) (70)
Rewiring the RNAs of influenza virus to prevent reassortment (2009) (70)
Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets (2015) (70)
Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs (2013) (70)
Sequential mutations in the NS genes of influenza virus field strains (1983) (69)
Universal influenza virus vaccines: need for clinical trials (2013) (69)
Infectious influenza A and B virus variants with long carboxyl terminal deletions in the NS1 polypeptides. (1987) (69)
Mutational analysis of the influenza virus vRNA promoter. (1993) (69)
Comparison of the three large polymerase proteins of influenza A, B, and C viruses. (1989) (68)
Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides. (1990) (67)
Influenza vaccines: present and future. (2002) (66)
A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice (2016) (66)
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate (2020) (66)
Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine. (2018) (66)
Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model (2018) (64)
Influenza B and C Virus NEP (NS2) Proteins Possess Nuclear Export Activities (2001) (64)
Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model (2017) (64)
Making Better Influenza Virus (2006) (64)
Nipah Virus Edits Its P Gene at High Frequency To Express the V and W Proteins (2009) (64)
A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. (2008) (63)
Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model (2017) (63)
Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. (2018) (63)
Is a Universal Influenza Virus Vaccine Possible? (2020) (62)
Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. (2007) (62)
Universal epitopes of influenza virus hemagglutinins? (2009) (62)
Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk Antibodies (2013) (62)
Interaction cloning of NS1-I, a human protein that binds to the nonstructural NS1 proteins of influenza A and B viruses (1996) (62)
P1 and P3 proteins of influenza virus are required for complementary RNA synthesis (1977) (61)
Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. (2009) (60)
Influenza A Virus RNA Polymerase Has the Ability To Stutter at the Polyadenylation Site of a Viral RNA Template during RNA Replication (1999) (60)
Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines (2007) (60)
Influenza C virus esterase: analysis of catalytic site, inhibition, and possible function (1989) (60)
Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge (2014) (59)
Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection. (2000) (59)
Attenuation of Influenza A Virus mRNA Levels by Promoter Mutations (1998) (58)
Rescue of Influenza A Virus from Recombinant DNA (1999) (57)
Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin (2013) (57)
Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins. (2015) (57)
Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes (1992) (57)
Mapping of the influenza virus genome. II. Identification of the P1, P2, and P3 genes. (1977) (57)
Influenza B virus genome: assignment of viral polypeptides to RNA segments (1979) (54)
NS1-Truncated Live Attenuated Virus Vaccine Provides Robust Protection to Aged Mice from Viral Challenge (2012) (53)
Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain. (2019) (53)
Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. (1999) (53)
Evolutionary relatedness of the predicted gene product of RNA segment 2 of the Tick-Borne Dhori virus and the PB1 polymerase gene of influenza viruses (1991) (52)
Molecular weights of RNA segments of influenza A and B viruses. (1978) (51)
Expression of influenza virus NS2 nonstructural protein in bacteria and localization of NS2 in infected eucaryotic cells (1985) (50)
A Seven-Segmented Influenza A Virus Expressing the Influenza C Virus Glycoprotein HEF (2008) (50)
Gaucher disease type 1: cloning and characterization of a cDNA encoding acid beta-glucosidase from an Ashkenazi Jewish patient. (1988) (50)
The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes. (1995) (49)
Antigenic variants of influenza viruses: marked differences in the frequencies of variants selected with different monoclonal antibodies. (1980) (49)
Development of novel influenza virus vaccines and vectors. (1997) (48)
A Novel Small Molecule Inhibitor of Influenza A Viruses that Targets Polymerase Function and Indirectly Induces Interferon (2012) (48)
Nucleotide sequence of the influenza A/duck/Alberta/60/76 virus NS RNA: conservation of the NS1/NS2 overlapping gene structure in a divergent influenza virus RNA segment. (1981) (48)
Identification of the defective genes in three mutant groups of influenza virus (1977) (48)
What can we learn from reconstructing the extinct 1918 pandemic influenza virus? (2006) (47)
Recognition of influenza A virus nucleoprotein by an H-2-restricted cytotoxic T-cell clone. (1984) (47)
Sequential passage of influenza virus in embryonated eggs or tissue culture: emergence of mutants. (1980) (46)
A Chimeric Influenza Virus Expressing an Epitope of Outer Membrane Protein F of Pseudomonas aeruginosa Affords Protection against Challenge with P. aeruginosa in a Murine Model of Chronic Pulmonary Infection (1998) (46)
A Reassortment-Incompetent Live Attenuated Influenza Virus Vaccine for Protection against Pandemic Virus Strains (2011) (46)
Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8+-T-Cell Epitope Derived from the Circumsporozoite Protein of Plasmodium yoelii (2003) (45)
Apical Budding of a Recombinant Influenza A Virus Expressing a Hemagglutinin Protein with a Basolateral Localization Signal (2002) (45)
Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies (2015) (45)
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses (2020) (44)
Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice (2010) (44)
The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA (2014) (44)
Influenza B viruses with site-specific mutations introduced into the HA gene (1995) (44)
Applications of a synthetic neuraminidase substrate. (1973) (44)
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines (2019) (43)
Difference in protein patterns of influenza A viruses. (1977) (43)
Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance (2018) (42)
Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors (2004) (42)
Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach (2019) (41)
Pause on avian flu transmission research. (2012) (41)
Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus (2019) (41)
Transfection-mediated recombination of influenza A virus (1992) (41)
Chimeric Influenza A Viruses with a Functional Influenza B Virus Neuraminidase or Hemagglutinin (2003) (40)
Evidence that the matrix protein of influenza C virus is coded for by a spliced mRNA. (1988) (40)
Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model (2019) (40)
Genetics of influenza viruses (1983) (40)
Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer (2011) (40)
Live attenuated influenza virus vaccines. Strains with temperature-sensitive defects in P3 protein and nucleoprotein. (1977) (39)
Analysis of an influenza A virus mutant with a deletion in the NS segment (1984) (39)
Influenza virus vectors. (1995) (38)
Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization (2017) (38)
Transmission Studies Resume for Avian Flu (2013) (37)
Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains (2015) (37)
Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins (2016) (37)
Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity (2016) (37)
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine (2020) (37)
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses (2021) (36)
A chromogenic substrate for the investigation of neuraminidases (1969) (36)
Efficient Transmission of Pandemic H1N1 Influenza Viruses with High-Level Oseltamivir Resistance (2012) (35)
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma (2019) (35)
Mechanism of attenuation of a chimeric influenza A/B transfectant virus (1992) (35)
Genetic composition of a high-yielding influenza A virus recombinant: a vaccine strain against "Swine" influenza. (1976) (35)
Selection and identification of influenza virus recombinants of defined genetic composition (1976) (35)
The influenza A virus protein PB1-F2 (2011) (34)
Broadly neutralizing antibodies target a haemagglutinin anchor epitope (2021) (34)
Don't censor life-saving science (2012) (34)
A Nine-Segment Influenza A Virus Carrying Subtype H1 and H3 Hemagglutinins (2010) (34)
Variation in Influenza Virus Genes (1989) (33)
RNA pattern of ‘Swine’ influenza virus isolated from man is similar to those of other swine influenza viruses (1976) (33)
Isolation of influenza C virus recombinants (1979) (33)
A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model. (2018) (33)
High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination (2015) (33)
Current Challenges in Vaccinology (2020) (32)
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine (2020) (32)
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. (1998) (32)
Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. (2018) (32)
Pause on Avian Flu Transmission Research (2012) (32)
Complementation and analysis of an NP mutant of influenza virus. (1989) (31)
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice (2019) (30)
Complete nucleotide sequence of the influenza C/California/78 virus nucleoprotein gene. (1984) (30)
Human acid beta-glucosidase: Northern blot and S1 nuclease analysis of mRNA from HeLa cells and normal and Gaucher disease fibroblasts. (1986) (30)
Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion (2017) (29)
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial (2022) (29)
Peering into the Crystal Ball: Influenza Pandemics and Vaccine Efficacy (2014) (29)
Nonsense mutations affecting the lengths of the NS1 nonstructural proteins of influenza A virus isolates. (1983) (29)
Expression of Transgenes from Newcastle Disease Virus with a Segmented Genome (2008) (28)
Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene (2003) (28)
Identification of Small Molecules with Type I Interferon Inducing Properties by High-Throughput Screening (2012) (28)
Isolation and characterization of influenza virus recombinants with high and low neuraminidase activity. Use of 2-(3'-methoxyphenyl)-n-acetylneuraminic acid to identify cloned populations. (1974) (28)
A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains (2019) (27)
Modulation of Host Gene Expression and Innate Immunity by Viruses (2005) (27)
Genetic structure and genetic variation of influenza viruses. (1980) (27)
Expression of the three influenza virus polymerase proteins in a single cell allows growth complementation of viral mutants. (1986) (27)
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate (2016) (27)
Synthesis of an ochre suppressor tRNA gene and expression in mammalian cells. (1984) (27)
Measurement of suppressor transfer RNA activity. (1983) (25)
An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations (2018) (25)
Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice. (2000) (24)
Proteins of a Polyhedral Cytoplasmic Deoxyvirus (1971) (24)
Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice (2017) (23)
RNA virus vectors: where are we and where do we need to go? (1998) (23)
Human Genes and Influenza (2008) (23)
Catching a Moving Target (2011) (23)
Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice (2018) (23)
In vitro translation of influenza virus messenger RNAs. (1976) (22)
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs (2021) (22)
Evidence that the matrix protein of influenza C virus is coded for by a spliced mRNA (1988) (22)
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts (2019) (22)
Assembly of lipid-containing viruses. (1974) (22)
The influenza C virus NS gene: evidence for a spliced mRNA and a second NS gene product (NS2 protein). (1986) (22)
Serum- and Glucocorticoid-Regulated Kinase 1 Is Required for Nuclear Export of the Ribonucleoprotein of Influenza A Virus (2013) (21)
Recombinant Vectors as Influenza Vaccines (2009) (21)
First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes (2021) (21)
Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. (1993) (21)
Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans (2018) (20)
Susceptibility of different strains of influenza A virus to the inhibitory effects of 2-deoxy-2,3-dehydro-n-trifluoracetylneuraminic acid (FANA). (1975) (20)
Einfluß von 2-Desoxy-2.3-dehydro-N-acetylneuraminsäure auf Myxovirus-Neuraminidasen und die Replikation von Influenza- und Newcastle Disease Virus / Influence of 2-Deoxy-2,3-dehydro-N-acetylneuraminic Acid on Myxovirus-neuraminidases and the Replication of Influenza- and Newcastle Disease Virus (1971) (20)
Antitumor properties of influenza virus vectors. (2000) (20)
Sequence analysis and receptor specificity of the hemagglutinin of a recent influenza H2N2 virus isolated from chicken in North America (2006) (20)
Is It Possible to Develop a “Universal” Inﬂuenza Virus Vaccine? Toward a Universal Inﬂuenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development (2017) (20)
A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein (2014) (20)
Influenza Virus Infection in Guinea Pigs Raised as Livestock, Ecuador (2012) (20)
Attenuated Influenza Virus Construct with Enhanced Hemagglutinin Protein Expression (2012) (20)
A Majority of Infectious Newcastle Disease Virus Particles Contain a Single Genome, while a Minority Contain Multiple Genomes (2012) (19)
Learning from our foes: a novel vaccine concept for influenza virus. (1999) (19)
Molecular Epidemiology of Influenza Virus (1983) (19)
Common Sequence at the 5′ Ends of the Segmented RNA Genomes of Influenza A and B Viruses (1978) (18)
Mutations within noncoding terminal sequences of model RNAs of Sendai virus: influence on reporter gene expression (1995) (18)
An avian tumor virus promoter directs expression of plasmid genes in Escherichia coli. (1981) (18)
A Novel Paramyxovirus? (2005) (17)
The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus (2018) (17)
Mutation of Neuraminidase Cysteine Residues Yields Temperature-Sensitive Influenza Viruses (1999) (17)
Influenza C virus RNA 7 codes for a nonstructural protein (1985) (17)
Detection of single base substitutions in influenza virus RNA molecules by denaturing gradient gel electrophoresis of RNA-RNA or DNA-RNA heteroduplexes. (1986) (17)
Degradation of single- and double-stranded RNA by frog virus 3. (1972) (17)
Expression of antisense RNA fails to inhibit influenza virus replication (1989) (17)
Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa. (1997) (17)
Cis-acting signals and trans-acting factors involved in influenza virus RNA synthesis. (1994) (16)
Inhibition of Viral Neuraminidase As a New Approach to the Prevention of Influenza (1975) (16)
Activity of Mouse Interferon in Human Cells (1971) (15)
Correction: Colocalization of Different Influenza Viral RNA Segments in the Cytoplasm before Viral Budding as Shown by Single-molecule Sensitivity FISH Analysis (2013) (15)
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice (2021) (14)
Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant (1995) (14)
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico (2022) (14)
Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies (2015) (14)
Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase (2019) (14)
Introduction of foreign sequences into the genome of influenza A virus. (1994) (13)
Interferon Action:Effect on the Formation of Poxvirus Specific Polysomes and Viral RNA (1970) (13)
Quantitative Determination of Neuraminidase-Active Foci in Cell Monolayer Cultures Infected with Influenza or Newcastle Disease Virus (1970) (13)
Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals (2020) (12)
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial (2022) (12)
Emergence and evolution of the 1918, 1957, 1968, and 2009 pandemic virus strains (2013) (12)
The makings of a killer (2002) (12)
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model (2021) (11)
The influenza virus protein PB 1F 2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein VARGA (2017) (11)
Genetic variation of viruses. (1980) (11)
Genetic engineering of infectious negative-strand RNA viruses. (1995) (11)
An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains (2019) (11)
Rapid RNA sequencing using double-stranded template DNA, SP6 polymerase, and 3'-deoxynucleotide triphosphates. (1986) (11)
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate (2020) (11)
Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein (2019) (11)
A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. (2013) (10)
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice (2022) (10)
Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells (2007) (10)
Genetic engineering of viruses and of virus vectors: a preface. (1996) (10)
GENOME DIVERSITY AMONG INFLUENZA A, B AND C VIRUSES AND GENETIC STRUCTURE OF RNA 7 AND RNA 8 OF INFLUENZA A VIRUSES (1981) (10)
Expression and function of suppressor tRNA genes in mammalian cells. (1986) (10)
Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Cancer-Specific Newcastle Disease Virus (2009) (10)
Genetic analysis of influenza virus. (1992) (9)
Virus-associated DNase: endonuclease in a polyhedral cytoplasmic deoxyvirus. (1972) (9)
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats (2021) (9)
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam (2022) (9)
H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model (2020) (8)
Orthomyxoviruses: Molecular Biology (2008) (8)
The Hemagglutinin Gene of Influenza Viruses (1978) (8)
Influenza Virus: The Biology of a Changing Virus (2010) (8)
Polyacrylamide gel electrophoresis of the RNAs of new influenza virus strains: an epidemiological tool. (1977) (8)
Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice (2022) (8)
Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice (2021) (7)
Response to Comment on “Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis” (2012) (7)
The great influenzaThe epic story of the deadliest plague in history (2004) (7)
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes (2021) (6)
A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters (2021) (6)
Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses. (2017) (5)
The 1918 influenza pandemic: lessons from the past raise questions for the future. (2008) (5)
Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants (2022) (5)
Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1 (2021) (5)
In memoriam--Richard M. Elliott (1954-2015). (2015) (5)
Novel method of detecting single base substitutions in RNA molecules by differential melting behavior in solution. (1988) (5)
An Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines (2021) (5)
[Influence of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid on Myxovirus-neuraminidases and the replication of influenza- and Newcastle disease virus]. (1971) (5)
Unsung Hero Robert C. Gallo (2009) (4)
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. (2022) (4)
A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro (2020) (4)
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice (2022) (3)
Profile of Charles M. Rice, Ralf F. W. Bartenschlager, and Michael J. Sofia, 2016 Lasker–DeBakey Clinical Medical Research Awardees (2016) (3)
Reply to Osterholm and Kelley: H5N1 in humans—the threat is not as bad as it may seem (2012) (3)
Series Introduction: New directions in vaccine research (2002) (3)
Infectious Influenza Viruses from cDNA-Derived RNA: Reverse Genetics (1993) (3)
Germ of an idea (1987) (2)
Influenza A VirusTransfectants withChimeric Hemagglutinins Containing Epitopes fromDifferent Subtypes (1992) (2)
Interaction between NS1 and Cellular MAVS Contributes to NS1 Mitochondria Targeting (2021) (2)
RAPID EVOLUTION OF HUMAN INFLUENZA VIRUSES (1986) (2)
Genetic variation of human influenza viruses (1980) (2)
Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine (2021) (2)
Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15. (2005) (2)
Pandemic Virus Characterization of the Reconstructed 1918 Spanish Influenza (2012) (2)
High-complexity extracellular barcoding using a viral hemagglutinin (2020) (2)
Viruses and the Innate Immune System (2005) (2)
INFLUENZA VIRUSES (ORTHOMYXOVIRIDAE) | Molecular Biology (1999) (2)
Evolutionary Lineages and Molecular Epidemiology of Influenza A, B, and C Viruses (1990) (2)
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults (2023) (1)
Aiphavirus-based expression vectors: Strategies and applications (2005) (1)
Influenza: A broadly protective antibody (2017) (1)
128 Toward a Universal Influenza Virus Vaccine (2012) (1)
MECHANISMS OF GENETIC VARIATION IN HUMAN INFLUENZA VIRUSES * (1980) (1)
Replication and Mortality in Mice and Neutrophils in Limiting Virus Functional Roles of Alveolar Macrophages Genes from the 1918 Pandemic Virus : Pathogenicity of Influenza Viruses with (2005) (1)
Fc-dependent effector functions of neutrophils induced by hemagglutinin stalk-specific antibodies (2016) (1)
Influenza pandemics: past and future (2006) (1)
Newcastle disease virus ( NDV ) expressing the spike protein of SARS-CoV-2 as vaccine candidate 1 2 (2020) (1)
Genome Plasticity of Influenza Viruses (2012) (1)
Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection (2013) (1)
Crystal Structure of the 1918 Human H1 Hemagglutinin Precursor (HA0) (2004) (1)
Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. (2014) (1)
Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface (2022) (1)
A Single Amino Acid Substitution in 1918 Inﬂuenza Virus Hemagglutinin Changes Receptor Binding Speciﬁcity (2005) (1)
A public broadly neutralizing antibody class targets a membrane-proximal anchor epitope of influenza virus hemagglutinin (2021) (1)
a colloquium entitkd " Genetic Engineering of Viruses and of Virus Vectors , " organized by Bernard Roizman and (2005) (0)
Glycosylation ofNeuraminidase Determines theNeurovirulence ofInfluenza A/WSN/33Virus (1993) (0)
The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines (2022) (0)
Systems for expression of recombinant Newcastle disease virus RNA and vaccines (1999) (0)
Forthcoming papers (2007) (0)
Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity (2022) (0)
GM swine influenza virus and uses thereof (2005) (0)
Understanding memory B cell responses to a chimeric-based universal influenza virus vaccine candidate (2020) (0)
Longitudinal analyses of human sera reveal expansions of antibody titers specific to previously-encountered pandemic and seasonal influenza viruses (P6366) (2013) (0)
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences: 356 (1416) (2001) (0)
A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in ferrets (2016) (0)
An open letter to the NSABB re the political and ethical implications of lethal virus development (2012) (0)
The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Inﬂuenza A and B Viruses (cid:1) (2011) (0)
HER-2-Nascent Polypeptide Chain Bound on Ribosomes Translating Influenza Virus Proteins Induces Differentiation of CD8+ Cells (2005) (0)
RNA expression systems of recombinant virus newcastle disease vaccines and corresponspentes. (1999) (0)
New Challenges to Health: The Threat of Virus Infection (review) (2004) (0)
Bioluminescence evaluation of efficacy of oncolytic treatment with Newcastle disease virus (NDV) in malignant pleural mesothelioma. (2009) (0)
The current understanding of the biology of the SARS-COV-2 virus (2020) (0)
Expression systems for recombinant negative-strand RNA viruses and vaccines. (1990) (0)
Generation of NS1-mutant Live attenuatedHuman Influenza vaccine candidate (2004) (0)
Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination (2022) (0)
Genetic variation of viruses. Introductory remarks. (1980) (0)
[Pig kidney neuraminidase: purification and properties]. (1968) (0)
Determination oftheMutation Rateofa Retrovirus (1988) (0)
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts (2019) (0)
Attenuated virus with negative polarity chain with altered interferon antagonist activity for use as vaccines and pharmaceuticals (1999) (0)
Table of Contents (1984) (0)
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial (2020) (0)
H-103 Towards a universal influenza virus vaccine (2018) (0)
Influenza virus pandemics: past and future (2015) (0)
New biochemical techniques for the characterization of viruses to assist the epidemiologist. (1980) (0)
New methods and interferon-deficient substrates for virus propagation. (1999) (0)
Complementation of influenza virus ts mutants using cell lines constitutively expressing influenza virus polymerase proteins (1985) (0)
Receptor destroying activities of RNA viruses: Identification of the catalytic site of the influenza C virus esterase (1988) (0)
Session Speakers Abstract SESSION I : Viruses : From Environments to Clinics Tuesday , June 19 th , 2018 8 : 30-10 : 00 AM IS 02 Towards a Universal Influenza Virus Vaccine (2018) (0)
Chimeric influenza viruses, recombinant DNA molecule, the method for producing an immunogenic formulation chimeric NDV, and method for inducing an immune response to infectious agents both (2006) (0)
Influenza A Virus PB1-F2: AS mall Protein with aB ig Punch (2007) (0)
A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains (2019) (0)
Towards developing a universal influenza vaccine (2018) (0)
Transmission of Pandemic H1N1 Inﬂuenza Virus and Impact of Prior Exposure to Seasonal Strains or Interferon Treatment (cid:1) (2009) (0)
A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies (2017) (0)
Oseltamivir-Resistant Inﬂuenza A Viruses Are Transmitted Efﬁciently among Guinea Pigs by Direct Contact but Not by Aerosol (cid:1) (2008) (0)
TheE3Protein ofBovineCoronavirus Isa Receptor-Destroying EnzymewithAcetylesterase Activity (1988) (0)
Cryo-EM Tomographic Analysis of a Universal Influenza Virus Vaccine Candidate (2017) (0)
Broadly Neutralizing Antibodies Against Conserved Epitopes of the Hemagglutinin Head are Robustly Recalled by a Novel H1N1 Virus (2020) (0)
Vaccination with recombinant neuraminidase protects against influenza virus infection in mice (2016) (0)
[Some notes on psychopathological origins of maladjustment of young conscripts in national service: a methodological contribution in the diagnosis of personality disorders]. (1994) (0)
PB1-F2 Expression by the 2009 Pandemic H1N1 Inﬂuenza Virus Has Minimal Impact on Virulence in Animal Models (cid:1) (2010) (0)
The Budding Capability of the Influenza Virus (2011) (0)
Oncolytic Newcastle Disease Virus Expressing a Checkpoint-Inhibiting Antibody As a Radiosensitizing Immunotherapy in a Murine Melanoma Model (2019) (0)
Correlation of High Evolutionary Rate of Influenza A Viruses in Man with High Mutation Rate Measured in Tissue Culture: A Hypothesis (1988) (0)
Genetically modified swine influenza virus and uses thereof (2005) (0)
The role of interferon in the pathogenesis of influenza virus infection (1997) (0)
Expression systems recombinant RNA virus and Newcastle disease vaccines (1999) (0)
Antitumor Properties of Influenza Virus Vectors 1 (2000) (0)
Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine. (2021) (0)
Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model (2018) (0)
Corrigendum (2007) (0)
Monoclonal antibodies recognizing a putative immunodominant epitope in the hemagglutinin stalk do not enhance influenza A virus mediated fusion activity (VIR5P.1156) (2015) (0)
Recombinant expression systems negative RNA viruses and vaccines chain. (1990) (0)
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice (2017) (0)
Prostate tumor cells infected with a recombinant influenza virus with truncated NS1 gene NS1 (1-126) activate cytolytic CD8+ cells which recognize non-infected tumors (2004) (0)
Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Speciﬁc Immune Response in Mice (cid:1) (2011) (0)
PigsVirus Transmission in Guinea Recombinant IgA Is Sufficient To Prevent (2014) (0)
New directions in vaccine research. (2002) (0)
Nuclear localization of NS1 and NS2 proteins in influenza a virus infected cells : Identification of nuclear signal sequences (1985) (0)
The Long Road to a Universal Influenza Virus Vaccine (2020) (0)
Inhibition of Influenza Virus Replication by 2-Deoxy-2,3-Dehydro-N-Trifluoroacetylneuraminic Acid (Fana) (1976) (0)
Interferon inducing genetically modified attenuated virus (1999) (0)
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes (2017) (0)
Influenza Viruses: Genome Structure, Transcription and Replication of Viral RNA (1987) (0)
Inhibitors of Viral Neuraminidase as Potential Antiviral Drugs (2018) (0)
12 – Permanent Expression of Influenza Virus Genes Coding for Transcriptase Complexes: Complementation of Viral Mutants (1987) (0)
Combined nanoemulsion and RIG-I agonist adjuvants-activation of diverse pathways for a broad spectrum influenza vaccine. (2016) (0)
Non-cumulative changes in the hemagglutinin genes of influenza C viruses (1985) (0)
Genetic Engineering of Viruses and Virus Vectors , " organized by Bernard Roizman and (2005) (0)
Recombination ofInfluenza A Virus (1992) (0)
Live Attenuated Influenza Virus Vaccines: NS1 Truncation as an Approach to Virus Attenuation (2011) (0)
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination (2023) (0)
Protection by a broadly neutralizing monoclonal antibody to pandemic Influenza requires selective Fc receptor engagement (P4216) (2013) (0)
Antibody idiotype plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity (ADCC) against influenza A virus (2016) (0)
Highly Conserved Regions of Inﬂuenza A Virus Polymerase Gene Segments Are Critical for Efﬁcient Viral RNA Packaging (cid:1) (2008) (0)
1015 Enhancing Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Newcastle Disease Virus (2009) (0)
The 1997 flu in Hong Kong infected only 18 patients, but killed 6 of them. Now, reverse genetics experiments have pinpointed the NS1 gene as a primary culprit. (2002) (0)
Swine flu virus engineered and uses thereof (2005) (0)
ISOLATION OF INFLUENZA C VIRUS RECOMBINANTS 1007 (0)
Biophysics in Virology | Biofisica (2020) (0)
Influenza Viruses: High Rate of Mutation and Evolution (2018) (0)
B cell convergence to distinct broadly reactive epitopes revealed by chimeric hemagglutinin vaccination (2022) (0)
In vitro reconstruction of the segmented negative-strand RNA viruses (2000) (0)
influenza A virus . A plasmid-based reverse genetics system for (1996) (0)
THE NONSTRUCTURAL GENE SEGMENT OF INFLUENZA A VIRUS: EXPRESSION OF NS1 PROTEIN IN MAMMALIAN CELLS; ANALYSIS OF A DELETION MUTANT (1984) (0)

This paper list is powered by the following services:

Other Resources About Peter Palese

en.wikipedia.org

What Schools Are Affiliated With Peter Palese?

Peter Palese is affiliated with the following schools:

Image Attributions

Image Source for Peter Palese